Company Insights

TPST customer relationships

Explore interactive graphBrowse insights index

TPST customers relationship map

Tempest Therapeutics (TPST): Customer relationships that shape a clinical-stage commercialization path

Tempest Therapeutics is a clinical-stage oncology company that develops small molecules and immune-mediated therapeutics and advances cell therapy assets through partnered manufacturing and regional licensing. The company monetizes through a combination of retained commercialization rights in core markets, strategic out-licenses for regional development, manufacturing partnerships for pivotal-stage assets, and selective asset sales that return value to shareholders. For investors tracking pathway risk and partner exposure, the relationship map around TPST-2003 and the recently announced asset transaction are the primary determinants of value realization. Learn more about the mapped relationships at Null Exposure: https://nullexposure.com/

How Tempest operates in practice — concise operating model signals

Tempest runs a focused, single-segment oncology research and development business concentrated on small-molecule and immune-mediated cancer therapies. The company is U.S.-centric in its asset base and operations and explicitly intends to retain significant development and commercialization rights, particularly in the United States, while partnering for regional development or manufacturing where strategically advantageous. Financially, Tempest is pre-revenue and clinical-stage (latest public figures show no revenue and a negative EBITDA), so partner execution and asset monetization events are the near-term drivers of enterprise value.

  • Contracting posture: seller/retainer — Tempest structures deals that preserve core rights and uses partners selectively for development, manufacturing, and regional commercialization.
  • Concentration and criticality: operations hinge on a small number of programmatic relationships (notably TPST-2003 partners and manufacturing sites), so partner performance is mission-critical.
  • Maturity: clinical-stage, no commercial revenues; balance-sheet management and asset transactions are active levers to fund development.

Relationship-by-relationship overview (complete coverage)

Below are plain-English summaries for every customer relationship found in the recent coverage, each paired with the originating press release.

What these relationships mean for investors

The relationship set reveals a deliberate dual strategy: retain U.S. commercial rights while partnering for regional development and third-party manufacturing. The Cincinnati Children’s relationship is a manufacturing-critical engagement that transitions TPST-2003 from research into pivotal production phases; manufacturing delivery is a tangible de-risking step for an asset entering pivotal development. The Novatim agreement removes China development from Tempest’s internal constraints and creates a route to value capture in a large market without direct commercialization expense. The Asset Purchase Agreement with Erigen and Factor and the associated warrant distribution are explicit capital-recycling measures that shift non-core assets off Tempest’s balance sheet while returning optional upside to shareholders.

Key financial context: Tempest’s most recent public metrics show no revenue, negative EBITDA (approximately -$26.3M), and a modest market capitalization (about $30.3M), underscoring the dependence on partnerships and transaction execution to create liquidity and sustain development. Insider ownership is meaningful, signaling alignment; institutional ownership is material but not dominant.

Practical due-diligence checklist for operators and investors

  • Confirm manufacturing scope and capacity at Cincinnati Children’s and the timetable for pivotal batch release and regulatory filings.
  • Review the Novatim license terms for China: exclusivity, milestones, and royalties to quantify upside and downside risk.
  • Obtain full terms of the Asset Purchase Agreement with Erigen and Factor, and model the economic effect of the warrant distribution on dilution and future capital needs.
  • Monitor upcoming clinical readouts and ISCT disclosures tied to TPST-2003 for milestone triggers that influence partner payments or regulatory submissions.

Bottom line: partner execution is the proximate value driver

Tempest’s path to commercialization is partner-dependent but strategically controlled—the company keeps core U.S. rights while leveraging external manufacturing and regional development partners to accelerate TPST-2003. If manufacturing execution at Cincinnati Children’s and regional development by Novatim proceed on schedule, Tempest converts clinical progress into tangible de-risking; if those partners falter, the company’s clinical-stage, pre-revenue profile leaves limited alternative levers beyond further transactions. For a structured relationship map and ongoing monitoring, visit Null Exposure: https://nullexposure.com/

Join our Discord